Kitron and RESPINOR AS have entered into a strategic long-term agreement. Kitron will be providing manufacturing and technical services as RESPINOR is getting ready for commercial manufacturing of its breakthrough technology: RESPINOR DXT. This is the first ultrasound-based sensors that can stick to the skin to provide continuous monitoring of our main breathing muscle, the diaphragm, leading to improved Intensive Care Unit (ICU) patient outcomes and shorter patient stays.

“Kitron and RESPINOR have already cooperated on prototypes, and this new agreement forms a solid platform for industrialization and ramp-up to make RESPINOR DXT available for critically ill patients worldwide,” said Trude Tingvoll, CEO of RESPINOR.

“Kitron has a long track record of helping customers convert ideas into manufacturable technology products, and we specifically look for companies with substantial growth potential. RESPINOR’s products will have an immediate positive impact on patients in ICU’s. This is especially relevant in these Corona fighting days, but also in the long term”, said Israel Losada Salvador, COO & Chief Sales Officer of Kitron.

‍